Reference
Villacorta R, et al. Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States. PharmacoEconomics : 13 Aug 2013. Available from: URL: http://dx.doi.org/10.1007/s40273-013-0078-x
Rights and permissions
About this article
Cite this article
Low-dose ustekinumab good value for money in psoriasis. PharmacoEcon Outcomes News 686, 8 (2013). https://doi.org/10.1007/s40274-013-0688-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0688-8